İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
Northrop Grumman Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $76.6B | |
|---|---|---|
| Revenue (ttm) | 43.6B | |
| Net income (ttm) | 4.5B | |
| EPS (ttm) | $31.7 | |
| Shares out | 142.1M | |
| P/E (trailing) | 17.4x | |
| P/E (forward) | 17.0x | |
| Dividend | $9.88 (1.79%) | |
| Volume | 554,503 | |
| Beta | -0.11 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $35.67B | $36.60B | $39.29B | $41.03B | $41.95B | +4.1% |
| Gross profit | $7.27B | $7.47B | $39.29B | $8.36B | $8.31B | +3.4% |
| Operating income | $5.65B | $3.60B | $2.54B | $4.37B | $4.51B | -5.5% |
| Net income | $7.01B | $4.90B | $2.06B | $4.17B | $4.18B | -12.1% |
| EPS (diluted) | $43.54 | $31.47 | $13.53 | $28.34 | $29.08 | -9.6% |
| EBITDA | $8.73B | $7.68B | $2.54B | $6.84B | $7.21B | -4.7% |
| R&D | $1.10B | $1.20B | $1.20B | $1.10B | $1.10B | +0.0% |
| SG&A | $3.60B | $3.87B | $4.01B | $3.99B | $4.03B | +2.9% |
Recent company headlines from major financial publishers.
Accelerated transition from low-rate initial production to full-rate production across the B-21 Raider bomber and Sentinel ICBM programs expands segment operating margins toward 12.0%, while international allied defense demand drives sales growth at the upper bound of 7.0%, supporting an 8.5% annual EPS growth path and lifting intrinsic value toward $820.75.
Northrop Grumman executes steadily against its $109.6 billion backlog, achieving full-year 2026 sales of $43.75B-$44.25B and 2027 top-line growth of 5% to 7%. Segment operating margins expand moderately from 11.3% in 2026 to 11.4%-11.6% by 2030, absorbing the $2.1 billion capex ramp in 2027 while adjusted free cash flow expands from $3.1B-$3.5B to $3.3B-$3.7B. Discounted at a 6.68% cost of equity, this yields a central fair value of $574.82 per share.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 5.7% | $622 | $640 | $659 | $683 | $710 |
| 6.2% | $584 | $597 | $612 | $629 | $648 |
| 6.7% | $554 | $564 | $575 | $587 | $602 |
| 7.2% | $528 | $536 | $545 | $555 | $566 |
| 7.7% | $507 | $513 | $520 | $528 | $536 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |